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A method for the early health technology
assessment of novel biomarker
measurement in primary
prevention programs
Douwe Postmus,a*† Gimon de Graaf,a Hans L. Hillege,a,b
Ewout W. Steyerbergc and Erik Buskensa
Many promising biomarkers for stratifying individuals at risk of developing a chronic disease or subsequent
complications have been identified. Research into the potential cost-effectiveness of applying these biomarkers
in actual clinical settings has however been lacking. Investors and analysts may improve their venture decision
making should they have indicative estimates of the potential costs and effects associated with a new biomarker
technology already at the early stages of its development. To assist in obtaining such estimates, this paper presents
a general method for the early health technology assessment of a novel biomarker technology. The setting con-
sidered is that of primary prevention programs where initial screening to select high-risk individuals eligible for
a subsequent intervention occurs, for example, prevention of type 2 diabetes. The method is based on quantifying
the health outcomes and downstream healthcare consumption of all individuals who get reclassified as a result
of moving from a screening variant based on traditional risk factors to a screening variant based on traditional
risk factors plus a novel biomarker. As these individuals form well-defined subpopulations, a combination of dis-
ease progression modeling and sensitivity analysis can be used to perform an initial assessment of the maximum
increase in screening cost for which the use of the new biomarker technology is still likely to be cost effective.
Copyright © 2012 John Wiley & Sons, Ltd.
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1. Introduction
Much research effort is currently directed at discovering novel biomarkers for identifying individuals at
risk of developing a chronic disease (primary prevention) or subsequent complications (tertiary preven-
tion). As these biomarkers provide additional information beyond standard clinical risk factors, applying
them in actual clinical settings is expected to result in improved risk stratification. This, in turn, may help
to optimize the selection of individuals eligible for a focused intervention, such as behavioral counsel-
ing or chemoprevention. Ultimately, this should improve the population’s health outcomes at affordable
(possibly lower) costs.
After a promising biomarker has been identified and a (prototype) technology has been developed
to measure this biomarker in actual clinical settings, its performance needs to be critically evaluated
before the new biomarker technology will eventually be adopted in clinical practice. According to
Hlatky et al. [1], such a critical assessment involves six phases, ranging from showing that the lev-
els of the novel biomarker differ between individuals with and without the outcome of interest (proof
of concept) to assessing whether using the biomarker improves health outcomes at an affordable cost
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(cost-effectiveness). In this traditional framework, cost-effectiveness analysis is conducted at the end of
the product development process. The results are intended to assist health policy makers in deciding
whether the new biomarker technology should be routinely adopted in clinical practice. This form of
health technology assessment (HTA) is what Pietzsch and Paté-Cornell [2] referred to as classical HTA,
to be distinguished from an initial assessment of the likely costs and effects associated with a new med-
ical technology at the early stages of its development process. This so-called early HTA is conducted
before the technology has been fully developed and serves to support health technology firms in making
appropriate product investment decisions.
Although appropriate quantification of the added predicted value of a novel biomarker over conven-
tional risk factors is a problem of active research and debate [3–9], research into the cost-effectiveness of
applying such a biomarker in actual clinical settings has so far been limited to two recent case studies in
the context of prioritizing patients waiting for coronary artery surgery [10, 11]. A more in-depth discus-
sion on how the cost-effectiveness of using prognostic biomarkers could be established seems therefore
desirable. To that end, this paper presents a general method for the early HTA of a novel biomarker
technology that is used, in combination with a set of conventional risk factors, as an initial screening test
to select high-risk individuals eligible for a subsequent preventive intervention. We illustrate the use of
the method in a case study related to the prevention of type 2 diabetes.
2. Added predictive value and cost-effectiveness of novel biomarker measurement
in primary prevention programs
IJzerman and Steuten [12] have recently provided a conceptual model of the medical technology devel-
opment process. According to their model, this process consists of four main stages: (i) basic research,
(ii) translational research, (iii) clinical research, and (iv) market access. Preceding each of these stages is
a decision gate where it has to be decided whether to proceed with the next stage, and if so, in what direc-
tion. In this paper, we assume that the basic research on biological mechanisms is completed and that
this has resulted in the identification of several candidate biomarkers. We are therefore at the decision
gate preceding the translational research phase, where it has to be decided which of these biomarkers
should be selected for further development, if any. The purpose of performing early HTA at this stage
of the product development process is to assist health technology firms in making realistic commercial
valuations of the conceived new products by providing for each potential new biomarker technology a
rough estimate of the maximum additional cost for which its intended clinical application is still likely
to be cost effective. In this section, we will describe how this upper bound on the technology’s cost, also
known as the commercial headroom available [13], can be estimated for an improved, biomarker-based
screening test.
Consider N individuals who participate in a primary prevention program. On the basis of the results
of an initial screening, individuals are classified intom ordinal risk categories, such as low, intermediate,
and high risk in case of three categories. Those who are considered to be at risk are offered a subsequent
intervention, which may be tailored to the risk category an individual is classified into (e.g., no interven-
tion in individuals who are being classified as low risk, a non-invasive and relatively safe intervention
in individuals who are being classified as intermediate risk, and an invasive and more risky interven-
tion in individuals who are being classified as high risk). Suppose that a decision maker can choose
between two variants of the risk stratification model: screening variant s1 in which the risk stratification
is based on a vector of cutoff points 1 D 11 ; : : : ; 1m10 on a risk score consisting of conventional
risk factors and screening variant s2 in which the risk stratification is based on a vector of cutoff points
2 D 21 ; : : : ; 2m10 on a risk score comprising the same conventional risk factors as well as a novel
biomarker. For clinically meaningful values of the cutoff points 1 and 2, consider the m by m reclas-
sification table that results from combining the risk classifications obtained under s1 and s2 (Table I).
Let Nkl denote the number of individuals within the kl th entry of the reclassification table (i.e., all
individuals who become classified in the kth risk category under s1 and in the l th risk category under






of the individuals are reclassified when applying s2
instead of s1.
The extent to which this reclassification can be considered an improvement can be determined in sev-
eral ways [14]. A measure of reclassification that has nowadays gained wide-spread acceptance is the
net reclassification index (NRI) [7]. The main idea behind this measure is to consider the reclassification
2734
Copyright © 2012 John Wiley & Sons, Ltd. Statist. Med. 2012, 31 2733–2744
D. POSTMUS ET AL.
Table I. The reclassification table that results from combining the risk classifications under s1 and s2.
Classification under s2
Risk category 1 Risk category 2 : : : Risk category m
Classification under s1 Risk category 1 N11 N12 : : : N1m






Risk category m Nm1 Nm2 : : : Nmm
of individuals who develop and who do not develop the event of interest separately. Moving from s1 to
s2 can then be considered an improvement when the proportion of subjects who move upward toward a
higher risk category is larger than the proportion of subjects who move downward toward a lower risk
category for individuals with the event and when the opposite holds for individuals without the event. To





denote the number of events and non-events within the kl th cell of the reclassification
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;
where nevent and nno event denote the total number of events and non-events in the total sample, respec-
tively. The novel biomarker is then considered to have incremental predictive value over the conventional
risk factors if the null hypothesis of NRI D 0 is rejected.
Although the NRI and other proposed measures of reclassification are useful for establishing the added
predicted ability of a novel biomarker, they do not directly provide insight into which of the risk strat-
ification models would be preferable from a societal perspective. To address this latter aspect, we have
to determine whether the increase in added predictive value is sufficient to make changing from s1 to s2
an efficient allocation of scarce healthcare resources, and this is the domain of health economic analysis
[15]. In this type of analysis, it is common practice to assume that all relevant health effects can be
aggregated into a single measure of effectiveness. The net monetary benefit (NMB) of an intervention
can then be calculated by assuming a threshold value of the decision maker’s willingness to pay for
one unit of health gain [15, 16]. The most common measure of effectiveness is the quality-adjusted life
year (QALY), and this is also the one that will be used in the case study. In the remainder of this paper,
we will therefore assume that the effectiveness of the two screening variants is evaluated in terms of
QALYs. The equations derived in this section are however applicable in all situations where the health
consequences are captured in terms of a single measure of effectiveness.
To determine the relative merits of the two screening variants, let ci and ei denote the average cost
and QALYs associated with screening variant si , and let  denote the willingness to pay (in terms of
monetary units) for a QALY. Screening variant s2 is then preferred over screening variant s1 if
NMB2  NMB1 > 0; (1)
where NMBi D ei  ci represents the average NMB associated with screening variant si . To use
Equation (1) to compute the headroom available to the improved, biomarker-based screening test, let
the treatment assignment indicator t i
kl
return the treatment that is assigned to the individuals in the kl th
entry of the reclassification table under screening variant si . For example, if under s1 treatment A is
offered to all individuals who are classified into risk category 2, t1
2l
D treatment A; 8l 2 f1; : : : ; mg.
The average cost and QALYs associated with screening variant si can then be written as
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denote the average cost and QALYs associated with applying treatment t i
kl
to the
individuals in the kl th entry of the reclassification table, and where ciscr denotes the average screening
cost under screening variant si . If we now define fkl D Nkl=N and scr D c2scr  c1scr, it follows by































Individuals who end up at one of the diagonal entries of the reclassification table are assigned to the
same treatment under both s1 and s2. Consequently, it is not required to consider these individuals’
QALYs and downstream healthcare consumption when choosing between the two screening variants.
In Equation (4), this is reflected by the fact that the average beneficial and/or harmful consequences





















, are only computed for those individuals who move upwards or downwards in risk classifi-
cation. For the biomarker-based screening variant to be cost effective, the overall increase in downstream
NMB (i.e., the right-hand side of Equation (4)) needs to be sufficiently large to offset the upfront increase
in screening cost, which are incurred by all individuals, irrespective of whether they are reclassified.
3. Parameter estimation
In this section, we will describe how the parameters at the right-hand side of Equation (4) can be
estimated at the decision gate preceding the translational research stage of the medical technology devel-
opment process. As the amount of clinical data available for estimating these parameters very much
depends on whether the biomarker in question has already been measured in a prospective cohort study,
we will make a distinction between technologies that aim at providing an alternative way of measuring
an existing biomarker and technologies that aim at measuring a completely new biomarker.
3.1. General considerations
As the initiation of a preventive intervention is expected to have cost and effect implications on the
remainder of a patient’s live, the appropriate time horizon for the economic evaluation of such interven-
tions is the patient’s lifetime [15]. In such situations, health economic analysts generally rely on disease
progression modeling to extrapolate from the event rates and treatment effects observed in clinical trials
and observational studies to what would be expected to happen over a lifetime [16]. The quantitative
models used for this purpose typically consist of several discrete health states reflecting the occurrence
of the events of interest and a set of transition intensities (or transition probabilities in case of a discrete-
time model) that govern the movement between these health states. The expected long-term cost and
effect consequences of an intervention can then be estimated by multiplying the average sojourn time in
each of the model’s health states by a cost and utility weight attached to these health states. To include
patient heterogeneity into the model, the logarithms of the transition intensities are sometimes expressed
as linear functions of a set of explanatory covariates, resulting in a so-called patient-level model. Disease
progression models that do not take into account patient heterogeneity are generally referred to as cohort
models [17].
For the individuals in the kl th cell of the reclassification table, the expected cost and QALY conse-
quences of moving from s1 to s2 will depend on three main aspects: (i) the cumulative disease incidence
Ikl./ as a function of the time since screening  that would be observed in this population in the absence
of screening; (ii) the reduction in cumulative disease incidence due to t1
kl




. Our strategy is to derive the health economic consequences that result from these changes
in the cumulative disease incidence through disease progression modeling. As the individuals from the
different cells of the reclassification table form well-defined subpopulations, we propose to fit separate
disease progression models to each of these subpopulations. In particular, let the vector ˛kl denote the
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3.2. Prospective data available
Many companies in the medical device industry do not only focus on developing novel equipment for
measuring promising new biomarkers but also on finding alternative (e.g., more efficient, less invasive,
or less risky) ways of measuring an existing biomarker, such as a multiplex ELISA that can simultane-
ously measure a whole panel of biomarkers. In such situations, it may already be possible to evaluate the
added predictive value of the selected (panel of) biomarker(s) over a set of conventional risk factors by
applying the currently available measurement techniques to blood, urine, or tissue samples collected in
an existing cohort study. Base-case values of the fractions fkl can then readily be derived from a reclassi-
fication table that is constructed from the data collected in this study. The same applies to all parameters
in ˛kl that directly depend on the incremental predicted value of the considered biomarker(s).
3.3. Prospective data not available
When dealing with a completely new biomarker, nothing will yet be known about the performance of this
biomarker in actual clinical settings. Initial values of fkl must then be derived from surrogate data, such
as early bench and animal testing, the performance of related but already clinically validated biomark-
ers, or expert judgment. A similar problem is encountered when specifying the parameters of the disease
progression model: although it may be possible to obtain some of the parameter values from previously
conducted economic evaluations, such as the costs and utilities attached to the model’s transient health
states, others depend on the incremental predictive value of the new biomarker and must therefore also
be derived from indirect sources. Probability Aggregation for Medical Device Assessment [2] is partic-
ularly suited for synthesizing evidence from multiple indirect sources, such as the results from several
pilot studies in different types of animal model. For a thorough discussion on how expert knowledge can
be elicited and incorporated in a probabilistic way, we refer the reader to [18].
4. Initial economic evaluation
After the base-case values of all parameters have been specified, the commercial headroom available to
the new biomarker technology, denoted bymaxscr , can be estimated by applying the algorithm depicted in
Figure 1. As the values of most parameters are still uncertain at the early stages of the medical technology
development process, the base-case analysis should be followed by an extensive amount of sensitivity
analysis to determine the robustness of the obtained results with respect to changes in the parameter
values. How the sensitivity analysis can best be conducted depends on the amount of clinical data avail-
able [19]. If the added predictive value of the considered biomarker has already been evaluated in a
prospective cohort study, the use of probabilistic sensitivity analysis (PSA) seems most appropriate as
probability distributions of the parameters of interest can then directly be derived from the data collected
within this study. On the other hand, unless expert knowledge has been elicited in a probabilistic way, the
use of PSA is generally not feasible when the novel biomarker has not yet been measured in a prospec-
tive cohort study. The use of a deterministic approach, such as one-way sensitivity analysis, would then
be more appropriate.
Figure 1. Algorithm for estimating maxscr for a specific set of parameter values.
Copyright © 2012 John Wiley & Sons, Ltd. Statist. Med. 2012, 31 2733–2744
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In a PSA, the uncertainty in one or more input parameters is propagated to uncertainty in the out-
come variable by repeatedly calculating maxscr for different samples from the (joint) distribution of the
input parameters. As the parameters of interest are treated as random variables, it seems logical to adopt a
Bayesian approach in estimating the probability distributions of these parameters. In particular, for given
values of the cutoff points, consider a random sample  j D .yj ; zj /; j D 1; : : : ; n, from the screening
population, where yj denotes the cell of the reclassification table where individual j is classified into
and zj all other measurements taken on individual j required to derive the joint distribution of the vector
˛ D .˛11; : : : ; ˛mm/0 . The  j s may be assumed to be independent across individuals, but yj and zj are
likely to be correlated within individuals. Let g. j jf11; : : : ; fmm; ˛/ denote the joint density of  j and
consider the factorization
g. j jf11; : : : ; fmm; ˛/D g.zj jyj ; ˛/g.yj jf11; : : : ; fmm/D g.zj jyj ; ˛yj /g.yj jf11; : : : ; fmm/: (5)
Marginally, g.yj jf11; : : : ; fmm/ is the frequency function of a discrete random variable with probabil-
ity fkl that individual j is classified into the kl th cell of the reclassification table. Given that yj ??yk ,
the observed number of individuals n11; : : : ; nmm in the different cells of the reclassification table is
multinomially distributed with probability vector .f11; : : : ; fmm/
0
. With a Dirch.a11; : : : ; amm/ con-
jugate prior used, the posterior distribution of .f11; : : : ; fmm/0 can be modeled as .f11; : : : ; fmm/0 
Dirch.a11Cn11; : : : ; ammCnmm/ [20]. To estimate the joint distribution of ˛kl , k; l D 1; : : : ; m, k ¤ l ,
it makes sense to condition the observations on the observed value of yj . The data zkl;1; : : : ; zkl;nkl can
then be treated as independent samples from each level of yj , such that separate multivariate Bayesian
models can be fitted to each of these samples to obtain the posterior distributions of ˛kl .
In a deterministic sensitivity analysis, no attempt is made to specify parameter uncertainty through
the use of probability distributions. Instead, reasonable lower and upper bounds are identified for each
of the parameters of interest, after which the actual sensitivity analysis is conducted by exploring in
a deterministic way how different combinations of the parameter values affect the value of maxscr . To
explore which of the input parameters have the highest impact on the outcome variable, it is common
practice to change one parameter value at a time, resulting in a so-called one-way sensitivity analysis. It
is also possible to perform a multi-way sensitivity analysis by changing two or more parameter values
simultaneously. However, the parameter values are still allowed to vary independently from each other
as nothing is known about the correlation between these parameters.
5. Illustrative case study
To demonstrate how our proposed method can assist in quantifying the headroom available to an
improved, biomarker-based screening test, we applied the method in a case study related to the
prevention of type 2 diabetes mellitus (DM2) and its associated microvascular and macrovascular
complications.
Figure 2. A discrete-time Markov model with three health states.
2738
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5.1. Clinical context
Lifestyle interventions have been previously shown to be cost-effective strategies to reduce the incidence
of DM2 in patients with pre-diabetes [21]. The primary prevention program considered in this case
study therefore consists of providing a lifestyle intervention to individuals who are at increased risk of
Table II. Model parameters, their initial values, and the sources used to obtain these values.
Symbol in text
Parameter (if defined) Value Source
Willingness to pay for a QALY  20,000 Reference value
Reclassification table
Size of the study population n 4977 [22]
Size of subpopulation kl nkl Table III [22]




Fraction of individuals in subpopulation kl fkl nkl=n
Seven-year incidence of DM2 in Ikl .7/ neventkl =nkl
subpopulation kl
in the absence of screening
Transition probabilities
Reduced risk of developing DM2 for the ˇintensive 0.70 [24]
intensive variant of the lifestyle-intervention
program (hazard ratio)
Reduced risk of developing DM2 for the basic ˇbasic 0.85 Expert judgment
variant of the lifestyle-intervention
program (hazard ratio)
Increased risk of death with diabetes (hazard ratio) ˇdiabetes 2.13 [23]




no diabetes to the diabetes state
in subpopulation kl










no diabetes to the diabetes state
in subpopulation kl
One-year probability of transiting from the p13.sex; age/ various National life tables
no diabetes to the death state
(sex and age dependent)
One-year probability of transiting from the p23.sex; age/ 1 exp log.1 p13.sex; age//ˇdiabetes
diabetes to the death state
(sex and age dependent)
Costs and utilities attached to the Markov model’s health states
Cost attached to the no diabetes state 0
Utility attached to the no diabetes state 0.84 [25]
Cost attached to the diabetes state 1805 [23]
Utility attached to the diabetes state 0.65 [23]
Costs of the lifestyle-intervention program
Cost of the intensive variant in the first year 800 [24]
Cost of the intensive variant in the second and third years 520 [24]
Cost of the intensive variant in all subsequent years 0
Cost of the basic variant in the first year 320 Expert judgment
Cost of the basic variant in the second and third year 160 Expert judgment
Cost of the basic variant in all subsequent years 0
Patient characteristics
Mean age in subpopulations 12 and 21 60 Expert judgment
Mean age in subpopulations 13 and 31 63 Expert judgment
Mean age in subpopulations 23 and 32 67 Expert judgment
Fraction of female subjects in subpopulation kl 0.543 [22]
Copyright © 2012 John Wiley & Sons, Ltd. Statist. Med. 2012, 31 2733–2744
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developing DM2. Screening variant s1 is based on existing clinical risk factors that have previously been
shown to have a strong predictive power for the risk of developing DM2. Screening variant s2 comprises
the same risk factors as well as a hypothetical new biomarker for predicting the onset of DM2, such
as a genetic marker related to metabolic programming by perinatal nutrition or a blood-based marker
related to lipotoxicity and its metabolic consequences. As a result of the initial screening, individuals
are classified into three risk categories. Individuals who are considered to be at high risk are offered an
intensive, 3-year lifestyle-intervention program consisting of both a dietary part and a physical activity
part. Individuals who are considered to be at intermediate risk are offered a more basic variant consist-
ing of a dietary component only. No intervention is offered to individuals who are considered to be at
low risk.
5.2. Structure of the disease progression model
To estimate the expected lifetime cost and QALY consequences of applying t i
kl
to subpopulation kl , we
constructed a discrete-time Markov model with three health states (see Figure 2 for a schematic repre-
sentation): no diabetes, diabetes, and death. We assumed the transition probabilities p13.sex; age/ and






of making a tran-
sition from the no diabetes to the diabetes state to depend on the subpopulation kl and on the treatment
t i
kl
that is assigned to these individuals under screening variant si . The applied cycle length was 1 year.
5.3. Parameter estimation
Table II shows a summary of all parameters of interest, their initial values, and the sources used to obtain
these values. As the novel biomarker included in s2 had not yet been evaluated in a prospective cohort
study, we had to rely on surrogate data to obtain initial values of some of these parameters. How this was
carried out exactly is briefly described in the subsections in the following text.
5.3.1. Specification of the fractions fkl . Salomaa et al. [22] evaluated whether a combined score of
four novel biomarkers (adiponectin, apolipoprotein B, C-reactive protein, and ferritin) could improve
the prediction of clinically incident diabetes over and above 11 classical risk factors, including blood
glucose. For the purpose of this case study, we assumed that the performance of this biomarker score
could serve as a proxy for the performance of the novel biomarker included under s2. This allowed us
to derive initial values of the fractions fkl from the reclassification table that the authors produced for
performing their NRI calculations (Table III) by setting 1 D 2 D .0:03; 0:15/0 and fkl D nkl=n.
5.3.2. Specification of the transition probabilities of the Markov model. We obtained the sex-dependent
and age-dependent transition probabilities from the no diabetes to the death state from national life
tables. We derived the transition probabilities from the diabetes to the death state from the transition
probabilities from the no diabetes to the death state by first converting them into instantaneous death
rates and then multiplying these death rates by a relative risk increase (hazard ratio) of ˇdiabetes D 2:13,







assumed that the cumulative incidence functions Ikl./ were exponentially distributed, which allowed
us to express the underlying instantaneous transition rates kl as [16]
kl D log.1 Ikl.//

: (6)





/total number of subjects (nkl ) after 7 years of follow-up
in the HEALTH 2000 cohort [22].
Predicted risk with classical risk factors
plus biomarker score
Low risk Intermediate risk High risk
Predicted risk with Low risk 29/3029 9/141 –
classical risk factors Intermediate risk 8/337 89/1228 15/68
High risk 0/1 5/27 33/146
2740
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 D 1 exp ˇt iklkl
		
; (7)
where ˇt ikl denotes the hazard ratio comparing individuals receiving the preventive intervention t i
kl
to
individuals not receiving a preventive intervention. For this case study, we set ˇintensive D 0:7, which
corresponds to the reduction in DM2 risk observed in the SLIM study [24]. As lifestyle interventions
consisting of a dietary component only are less effective than lifestyle interventions consisting of both
a dietary and a physical component, we assumed the value of ˇintermediate to be slightly higher and set
equal to 0.85. We subsequently applied Equations (6) and (7) to transform the 7-year diabetes incidences








5.3.3. Cost and utility estimates. We obtained the cost and utility estimates attached to the Markov
model’s transient health states from previously conducted economic evaluations. We derived the costs
associated with the intensive variant of the lifestyle-intervention program from the SLIM study and set
equal to EUR 800 for the first year and EUR 520 for the second and third years. For the basic variant of
the lifestyle-intervention program, we set these costs equal to EUR 320 and EUR 160, respectively.
5.3.4. Specification of the patient characteristics. As we did not have access to the original data used
to construct Table III, we had to rely on expert judgment to obtain initial values of the mean age and
male/female ratio in the different subpopulations kl . Age is generally considered to be a strong predictor
for the development of DM2, and this was taken into account when specifying the base-case values of
the mean age in each of the subpopulations kl . In particular, we set the mean age in individuals who
were classified as low risk under one of the screening variants and high risk under the other equal to 63,
which corresponds to the third quartile of the age distribution observed in the HEALTH 2000 cohort.
We subsequently assumed the mean age in individuals who are classified as low risk under one screen-
ing variant and intermediate risk under the other to be slightly lower and set equal to 60, whereas we
assumed the mean age in individuals who are classified as intermediate risk under one screening variant
and high risk under the other to be slightly higher and set equal to 67. Sex is usually not associated with
the development of DM2. We therefore assumed the fraction of female subjects in each of the subpop-
ulations kl to be equal to 0.543, which corresponds to the fraction of female subjects observed in the
HEALTH 2000 cohort.
5.4. Results of the initial economic evaluation
For the base-case values of the model parameters, we found the commercial headroom available to the
biomarker-based screening variant to be equal to EUR 75. To determine the robustness of this result with
respect to small changes in the parameter values, we performed a one-way sensitivity analysis (Figure 3).
The amount of headroom available was most sensitive to changes in the effect of the two lifestyle inter-
ventions and to changes in the mean age in each of the subpopulations kl . Changing the 7-year disease
incidences Ikl.7/ had a less profound impact on maxscr . We also varied the male/female ratios in each
of the subpopulations kl as well as the different cost components of the two lifestyle interventions, but
these changes only had a marginal impact on the amount of headroom available (results not shown).
5.5. Implications
On the basis of the results of our initial economic evaluation, we can conclude that if the cost of measur-
ing the novel biomarker is expected to be relatively low, there seems still sufficient room for improving
the predictive performance of the existing risk classification models to warrant further research on novel
biomarkers that are independently associated with the onset of DM2. On the other hand, if the unit cost
of measuring the novel biomarker is likely to exceed EUR 100, it may be more fruitful to focus the
research effort on identifying prognostic biomarkers that have a strong correlation with one of the estab-
lished risk factors but are less expensive and/or invasive to measure. However, whether such a biomarker
would actually be suitable as a substitute for an established risk factor not only depends on the effect
size of this new biomarker compared with the established risk factor but also on its whole correlation
Copyright © 2012 John Wiley & Sons, Ltd. Statist. Med. 2012, 31 2733–2744
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(b) Treatment effect and 7-year disease incidences
Mean age in subpopulation 12
Mean age in subpopulation 21
Mean age in subpopulation 23







Figure 3. Results of the one-way sensitivity analysis.
structure with all the other variables included in the risk stratification model. This should be considered
as well when making a go/no-go decision on the search for such a biomarker.
When performing our analysis, we implicitly assumed that the hypothetical new biomarker will have
similar predictive capabilities as the biomarker risk score considered by Salomaa et al. [22]. It should
therefore be noted that if such a biomarker is expected to have better (worse) capabilities in reclassifying
subjects at risk of developing DM2, the cost of measuring the biomarker may be higher (should be lower)
than the suggested upper bound of EUR 100. However, care should be taken not to raise the amount of
headroom available too easily as the results of previous studies suggest that the initial expectations of a
new biomarker have often been too optimistic, with disappointments in later phases of analyses [1].
6. Discussion
Moving from a screening variant based on traditional risk factors to a screening variant based on tra-
ditional risk factors plus a novel biomarker results in a reclassification of some of the individuals. To
determine the maximum increase in screening cost for which this reclassification is still likely to be cost
effective, we first restructured the decision problem in such a way that part of the parameters of interest
could be estimated through disease progression modeling. We then described how these models could be
combined with estimated values of the degree of reclassification to obtain initial estimates of the amount
of commercial headroom available. We illustrated our method in a case study related to the prevention
of DM2, where we used a Markov model with three health states to perform an initial economic evalua-
tion of a potential new biomarker technology by using published data on the NRI of related but already
clinically validated biomarkers.
Pietzsch and Paté-Cornell [2] have previously suggested a general method for the early HTA of new
medical devices. Their approach requires an analyst to represent the dependency between the decision
variable and the outcome of interest through a sequence of primary and intermediate effect variables,
thereby allowing the analyst to obtain concrete realizations of the outcome variable by sampling from a
series of conditional probability distributions. Our method is similar in the sense that we also determine
the effect of the decision variable (biomarker-based screening or screening without using the biomarker)
on the outcome of interest (the amount of headroom available) by sampling from a series of conditional
probability distributions. However, instead of requiring the analyst to provide exact functional forms
for each of these probability distributions, we have restructured the decision problem in such a way
that some of these distributions can be approximated through disease progression modeling. This makes
our method easier to apply in situations where there are no clear functional relationships between the
variables of interest, such as in our case study related to the prevention of DM2.
A limitation of performing early HTA is that there is generally only a limited amount of clinical
data available with which to populate the decision models. This implies that to be able to compute the
amount of headroom available, it is sometimes required to make strong assumptions on some of the
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unknown parameters, and in this respect, our method is no exception. In our case study, this became
especially apparent when specifying the values of the cutoff points used to differentiate between low-
risk, intermediate-risk, and high-risk individuals, the changes in the distribution of individuals across
these three risk categories as a result of moving from the traditional risk classification model to the
biomarker-based risk classification model, and the patient characteristics in each of the six subpopula-
tions. The specification of the cutoff points should ideally be based on the ratio of the costs associated
with a false positive and the benefits foregone because of a false negative [14], and the NMB framework
provides a means of formally quantifying this trade-off. However, even with such a formal framework in
place, it remains difficult to determine the values of the cutoff points in an ‘objective’ way: (i) analysts
are still required to make a value judgment about the willingness to pay per unit of health gain, and (ii)
the effectiveness of the administered treatments is likely to depend on the selected cutoff points, but the
clinical data required to estimate this dependency may not be available.
Although the use of our method provides insight into the amount of headroom available to a novel
biomarker, it does not directly provide an answer to the question of whether a medical technology firm
should proceed with developing a technology that can measure this biomarker in actual clinical settings.
To address this latter aspect, the results of the initial economic evaluation must first be translated into
an estimate of the technology’s maximum sales price by applying the principle of value-base pricing
[26]. This estimate can then be fed into an appropriate product investment evaluation method, such as
the one proposed by Girling et al. [27], to determine whether the expected post-market cash flows are
sufficiently large to warrant further investments to transform the current concept into a fully developed
end product. When performing such a return-on-investment analysis for a specific biomarker technol-
ogy, one should be aware that the technology can potentially be used for multiple purposes, for example,
not only as a screening test for selecting individuals eligible for a subsequent preventive intervention
but also as a test for monitoring treatment response once the disease has been clinically established. All
these potential uses of a new biomarker technology should ideally be taken into account when deter-
mining the technology’s maximum sales price and estimating the subsequent expected post-market cash
flows. However, performing such a comprehensive return-on-investment analysis is not straightforward,
and future research on this problem area seems desirable.
To conclude, we presented a method for the early HTA of novel biomarker measurement in primary
prevention programs and applied this method in a case study related to the prevention of DM2. Although
we have focused on the use of the biomarker as a screening test for identifying individuals at risk of
developing a chronic disease, our approach of first identifying the parameters of interest and then restruc-
turing the decision problem in such a way that part of these parameters can be estimated through disease
progression modeling seems more generally applicable. Future research effort may therefore be directed
at exploring whether it is possible to quantify the clinical value of other potential applications of a new
biomarker technology, such as a diagnostic test or a disease monitoring test, in a similar way.
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